TRAIL, Soluble, Recombinant, Human (Apo-2L, TNFSF10, CD253)

TNF-related apoptosis-inducing ligand (TRAIL, Apo2L,CD253, TNFSF10) is a type II transmembrane protein of about 34kD. Like most members of the tumor necrosis factor (TNF) superfamily of cytokines TRAIL can be cleaved at the cell surface by metalloproteases to form a soluble molecule. Active TRAIL forms trimers and specifically binds to fi ve distinct receptors: TRAIL-R1 (DR4, Apo2,CD261, TNFRSF10A), TRAIL-R2 (DR5, KILLER, TRICK2A,TRICK2B, CD262, TNFRSF10B), TRAIL-R3 (DcR1,LIT, TRID, CD263, TNFRSF10C), TRAIL-R4 (DcR2,TRUNDD, CD264, TNFRSF10D), and osteoprotegerin (OPG, OCIF, TNFRSF11B). Trimerized TRAIL triggers apoptosis upon ligation of cell surface TRAIL-R1 and/or TRAIL-R2 by inducingthe formation of the so-called multiprotein death-inducing signaling complex (DISC). Sequence: The extracellular domain of human TRAIL (aa95-281) is fused at the N-terminus to a FLAG(R)-tag. Biological Activity: Induces apoptosis of human Jurkat T cells in a concentration range of 5-50ng/ml in the presence of 1ug/ml TNF Ligands Enhancer. In the absence of TNF Ligands Enhancer, TRAIL, Soluble (human) (recombinant) is poorly active. Storage and Stability: Lyophilized powder may be stored at -20°C. Stable for 12 months after receipt at -20°C. Reconstitute with sterile ddH2O. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Reconstituted product is stable for 6 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.